for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Glenmark Pharmaceuticals Ltd

GLEN.NS

Latest Trade

299.85INR

Change

11.30(+3.92%)

Volume

1,927,084

Today's Range

287.10

 - 

301.50

52 Week Range

270.00

 - 

705.90

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
288.55
Open
290.00
Volume
1,927,084
3M AVG Volume
27.88
Today's High
301.50
Today's Low
287.10
52 Week High
705.90
52 Week Low
270.00
Shares Out (MIL)
282.17
Market Cap (MIL)
84,608.13
Forward P/E
11.61
Dividend (Yield %)
0.67

Next Event

Q2 2020 Glenmark Pharmaceuticals Ltd Earnings Release

Latest Developments

More

Glenmark Pharmaceuticals Gets ANDA Approval For Abiraterone Acetate Tablets USP, 250 Mg

Glenmark Pharma Gets Tentative ANDA Approval For Dimethyl Fumarate Capsules

Glenmark Pharmaceuticals Gets Nod For Combination Of Remogliflozin Etabonate And Metformin Hydrochloride

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Industry

Biotechnology & Drugs

Contact Info

B D S Marg

Chakala, Off Western Express Highway

Andheri (E),

+91.22.40189999

http://glenmarkpharma.com/

Executive Leadership

Glenn Mario Saldanha

Executive Chairman of the Board, Chief Executive Officer, Managing Director

V. S. Mani

Global Chief Financial Officer, Executive Director

Harish Kuber

Compliance Officer, Company Secretary

Cherylann Pinto

Director - Corporate Affairs, Executive Director

Rajesh V. Desai

Non-Executive Director

Key Stats

2.59 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

89.7K

2018

91.0K

2019

98.7K

2020(E)

106.0K
EPS (INR)

2017

42.150

2018

28.490

2019

26.860

2020(E)

25.829
Price To Earnings (TTM)
10.87
Price To Sales (TTM)
0.84
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
6.41
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Glenmark Pharmaceuticals To Partner With Novartis In Brazil

* GLENMARK TO PARTNER WITH NOVARTIS TO PROMOTE, COMMERCIALIZE AND DISTRIBUTE THREE RESPIRATORY PRODUCTS IN BRAZIL

BRIEF-Glenmark Pharmaceuticals Submitts NDA To U.S. FDA For Ryaltris

* GLENMARK PHARMACEUTICALS - SUBMITTED NDA TO U.S. FDA FOR LEADING RESPIRATORY PIPELINE CANDIDATE RYALTRIS Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharma Says Co Suspended Trial Conducted at Malpani Hospital After Alleged Irregularities

* CLARIFIES ON NEWS ITEM ABOUT CO GETTING NOTICE OVER MISCONDUCT IN CLINICAL TRIALS

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Clobetasol Propionate Topical Solution USP

* GETS ANDA APPROVAL FOR CLOBETASOL PROPIONATE TOPICAL SOLUTION USP

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Tacrolimus Ointment, 0.1 Pct

* SAYS CO GETS ANDA APPROVAL FOR TACROLIMUS OINTMENT, 0.1 PERCENT Source text - http://bit.ly/2HKxf5K Further company coverage:

BRIEF-Glenmark Pharmaceuticals, Helsinn Group Enter Into Agreement For Launch Of Akynzeo In India And Nepal

* SAYS CO, HELSINN GROUP ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR LAUNCH OF AKYNZEO IN INDIA AND NEPAL

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval From U.S. FDA For Clobetasol Propionate Spray, 0.05 Pct

* SAYS CO GETS ANDA APPROVAL FROM U.S. FDA FOR CLOBETASOL PROPIONATE SPRAY, 0.05 PERCENT

BRIEF-Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals

* GLENMARK PHARMACEUTICALS - ENTERED INTO EXCLUSIVE DEAL WITH SAM CHUN DANG PHARM

BRIEF-India's Glenmark Pharmaceuticals Dec-Qtr Consol Profit Falls 78 Pct

* DEC QUARTER CONSOL PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 4.77 BILLION RUPEES LAST YEAR

BRIEF-Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864

* GETS PERMISSION BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION FOR PHASE IIB DOSE RANGE FINDING STUDY FOR GRC 27864 Source text - http://bit.ly/2mEqR6R Further company coverage:

BRIEF-Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India

* LAUNCHES BIOSIMILAR OF ADALIMUMAB IN INDIA Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Norethindrone Acetate, Ethinyl Estradiol Tablets

* GETS ANDA APPROVAL FOR NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS USP AND FERROUS FUMARATE TABLETS Source text - http://bit.ly/2BGPRjs Further company coverage:

BRIEF-Glenmark Pharmaceuticals Meets Primary Clinical Endpoint In Phase 3 Study Of Ryaltris

* SAYS MET ITS PRIMARY CLINICAL ENDPOINT IN A PHASE 3 STUDY EVALUATING SAFETY OF RYALTRIS

BRIEF-Glenmark Pharma Says Closed DCP For Generic Seretide Accuhaler In Nordic Region​

* ANNOUNCES CLOSURE OF DECENTRALISED REGISTRATION PROCEDURE (DCP) FOR GENERIC SERETIDE ACCUHALER IN NORDIC REGION Source text - http://bit.ly/2ByD8zw Further company coverage:

BRIEF-Glenmark Pharma Says U.S. FDA issues 7 Form 483 observations for co's ‍Baddi Unit

* GLENMARK PHARMACEUTICALS SAYS BADDI UNIT UNDERWENT AN U.S. FDA AUDIT FROM NOVEMBER 6, 2017 TO NOVEMBER 11, 2017

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for HAILEY Fe 1/20 tablets ​

Glenmark Pharmaceuticals Ltd * Gets ANDA approval for HAILEY Fe 1/20 tablets Source text - http://bit.ly/2hRulnp Further company coverage:

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for Haileytm 24 FE 1 mg/20 mcg​

* Gets ANDA approval for Haileytm 24 fe 1 mg/20 mcg Source text for Eikon: Further company coverage:

BRIEF-India's Glenmark Pharmaceuticals Sept-qtr consol profit falls about 4 pct

* Sept quarter consol profit 2.14 billion rupees versus profit of 2.24 billion rupees last year

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for aprepitant capsules USP​

* Says Glenmark Pharmaceuticals receives ANDA approval for aprepitant capsules USP Source text - http://bit.ly/2gHsEFg Further company coverage:

BRIEF-Glenmark Pharmaceuticals gets ANDA approval from U.S. FDA for desonide lotion

* Gets ANDA approval from U.S. FDA for desonide lotion, 0.05 percent Source text - http://bit.ly/2frnZGG Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up